BiologicalDrug
Brexucabtagene autoleucel clinical trials
Also written KTE-X19 and Tecartus.
- studies test it
- 10
- open now
- 2
- in phase 3
- 0
- first study started
- 2015
Keep track of what changes. Save the brexucabtagene autoleucel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Kite, A Gilead Company (7) · H. Lee Moffitt Cancer Center and Research Institute (2) · Masonic Cancer Center, University of Minnesota (1)
Often tested with
Tested in the same studies.
Tisagenlecleucel (1) · Axicabtagene ciloleucel (1) · Fludarabine (1) · Cyclophosphamide (1) · Idecabtagene vicleucel (1) · Lisocabtagene maraleucel (1) · Pirtobrutinib (1)
Studies
Open first, then newest update. How each study uses brexucabtagene autoleucel is read from its arms, and is right about nine times in ten.
Testing it · 10
- Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06144606Written as Tecartus
- Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCLRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06553872Written as Brexucabtagene Autoleucel
- Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)CompletedPhase 2Kite, A Gilead CompanyNCT04880434Written as Brexucabtagene autoleucel
- Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2Kite, A Gilead CompanyNCT06253663Written as KTE-X19
- Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin LymphomaCompletedPhase 1/2Kite, A Gilead CompanyNCT02625480Written as Brexucabtagene Autoleucel (KTE-X19)
- Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)CompletedPhase 2Kite, A Gilead CompanyNCT02601313Written as brexucabtagene autoleucel
- Study of Brexucabtagene Autoleucel in Adults With Rare B-cell MalignanciesTerminatedPhase 2Kite, A Gilead CompanyNCT05537766Written as Brexucabtagene Autoleucel
- MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03642626Written as Tecartus
- A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)CompletedPhase 1/2Kite, A Gilead CompanyNCT02614066Written as brexucabtagene autoleucel
- Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaTerminatedPhase 1Kite, A Gilead CompanyNCT03624036Written as brexucabtagene autoleucel
Given in every arm · 4 — brexucabtagene autoleucel is usual care beside what is tested
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT07892027Written as Brexucabtagene Autoleucel
- Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT07763210Written as Brexucabtagene Autoleucel
- Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT07673367Written as Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus)
- CAR-T-cell Treatment for Untreated High Risk MANtle Cell LymphomaRecruitingPhase 2Christian Schmidt, MDNCT06482684Written as KTE-X19
Codes
What other systems call brexucabtagene autoleucel · ClinicalTrials.gg INT001273
- MeSH (NLM) C000705347brexucabtagene autoleucelConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 4MD2J2T8SJBREXUCABTAGENE AUTOLEUCELConfirmed FDA, NLM, Wikidata
- RxNorm 2387277One source FDA
- Wikidata Q97704053brexucabtagene autoleucelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170439Brexucabtagene AutoleucelOne source FDA
- DrugBank DB15699One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705347 | brexucabtagene autoleucel | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 4MD2J2T8SJ | BREXUCABTAGENE AUTOLEUCEL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2387277 | — | One source FDA |
| Wikidata | Q97704053 | brexucabtagene autoleucel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170439 | Brexucabtagene Autoleucel | One source FDA |
| DrugBank | DB15699 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.